"BofA analyst Jason Gerberry raised his price target to $626 from $569, keeping a Neutral rating. Based on the combined TETON-1 and TETON-2 results, BofA sees a role for Tyvaso as both a monotherapy for patients unable to tolerate anti-fibrotics and as an adjunct therapy on top of anti-fibrotics."
"Wells Fargo raised its target to $575 from $486, also maintaining an Equal Weight rating. The firm characterized the TETON-1 data as 'a nice win' and now assigns a 95% probability of success for an IPF approval."
"United Therapeutics has spent years building a dominant PAH franchise. Tyvaso DPI generated $338.6 million in Q4 2025, up 24% year over year, making it the company's primary growth engine."
"CEO Martine Rothblatt framed the pipeline moment clearly: 'The breakthrough results...'"
United Therapeutics experienced a 12% surge in pre-market trading following positive TETON-1 trial results. The data supports Tyvaso's expansion into idiopathic pulmonary fibrosis, addressing significant unmet needs. Analysts from BofA and Wells Fargo raised their price targets, reflecting confidence in Tyvaso's dual role as a monotherapy and adjunct therapy. The TETON-1 results are seen as a pivotal moment for United Therapeutics, potentially marking a significant product-line extension beyond pulmonary arterial hypertension, which has been the company's primary focus for years.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]